NASDAQ:CFRX ContraFect (CFRX) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free CFRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.04▼$13.02Volume910,200 shsAverage Volume1.39 million shsMarket Capitalization$535,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ContraFect alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About ContraFect Stock (NASDAQ:CFRX)ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> CFRX Stock News HeadlinesApril 16, 2024 | finance.yahoo.comRegenETP, Inc. (RGTPQ)January 9, 2024 | morningstar.comContraFect Corp CFRXQNovember 19, 2023 | morningstar.comContraFect Corp CFRXNovember 14, 2023 | washingtonpost.comContraFect: Q3 Earnings SnapshotOctober 23, 2023 | benzinga.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 16, 2023 | msn.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | finance.yahoo.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyOctober 10, 2023 | benzinga.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketSeptember 21, 2023 | finance.yahoo.comCFRX: IND Application for CF-370 Submitted to FDA…September 19, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | finance.yahoo.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 18, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370August 28, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 17, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 15, 2023 | markets.businessinsider.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 14, 2023 | sfgate.comContraFect: Q2 Earnings SnapshotAugust 14, 2023 | finance.yahoo.comContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 25, 2023 | money.usnews.comContraFect CorpJuly 6, 2023 | msn.comContraFect (CFRX) Price Target Decreased by 97.37% to 5.10June 27, 2023 | msn.comContraFect enters a warrant exercise transaction for $9.6MJune 27, 2023 | finance.yahoo.comContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionJune 22, 2023 | marketwatch.com8-K: CONTRAFECT CorpJune 22, 2023 | finance.yahoo.comCFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…June 20, 2023 | finance.yahoo.comContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensJune 9, 2023 | msn.comContraFect Gains with Key Data Presentation Set for Next WeekSee More Headlines Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.70% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($19.92) per share Price / Book0.00Miscellaneous Outstanding Shares10,700,000Free Float10,639,000Market Cap$535,000.00 OptionableNot Optionable Beta0.29 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Roger James Pomerantz FACP (Age 66)M.D., Chairman, CEO & President Comp: $970.72kMr. Michael Messinger CPA (Age 48)Chief Financial Officer Comp: $543.14kMs. Natalie Bogdanos J.D. (Age 54)General Counsel, Corporate Secretary & Data Protection Officer Comp: $531.2kMr. Matthew Salamone P.H.R.SPHR, Vice President of Human ResourcesDr. Gary Woodnutt (Age 66)Senior Vice President of Translational Sciences & Preclinical Development Dr. William Garrett Nichols M.D. (Age 54)M.S., Interim Chief Medical Officer More ExecutivesKey CompetitorsOncoSec MedicalNASDAQ:ONCSSalarius PharmaceuticalsNASDAQ:SLRXAltamira TherapeuticsNASDAQ:CYTONotable LabsNASDAQ:NTBLInMed PharmaceuticalsNASDAQ:INMView All Competitors CFRX Stock Analysis - Frequently Asked Questions How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) posted its earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($22.64) by $12.24. When did ContraFect's stock split? ContraFect shares reverse split before market open on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX). This page (NASDAQ:CFRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredRevealed: The Unknown Biotech Powering AI in HealthcareThe CEO of Google predicted this is "one of the most important things for humanity." We're standing at the ...Behind the Markets | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraFect With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.